

Not an actual patient.

Make the most of your
next appointment

Please see Important Safety Information
throughout and full Prescribing Information.

 **PLUVICTO**[®]
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

Thinking about your next mCRPC treatment

Looking for another treatment option for your metastatic castration-resistant prostate cancer (mCRPC) can be challenging

There is a lot to consider when deciding on your next treatment with your doctor. However, getting ready to talk to your doctor about what's next in your treatment journey can help.

Several treatment options are available that could benefit you at this step in your journey. After you've received treatment with a type of chemotherapy and an androgen receptor pathway inhibitor, radioligand therapy (RLT) could be an option.

Using this guide can help you have a meaningful conversation with your doctor about your next treatment choice and whether RLT is right for you. Remember that your treatment team is there to answer any questions you might have.

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:

- has spread to other parts of the body (metastatic), and
- has already been treated with other anticancer treatments

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

PLUVICTO may cause serious side effects, including:

- **Low level of blood cell counts.** Tell your doctor right away if you develop any new or worsening symptoms, including:
 - Tiredness or weakness
 - Pale skin
 - Shortness of breath
 - Bleeding or bruising more easily than normal or difficulty stopping bleeding
 - Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers
- **Kidney problems.** Tell your doctor right away if you develop any new or worsening symptoms, including passing urine less often or passing much smaller amounts of urine than usual

Please see additional Important Safety Information throughout and full Prescribing Information.



Preparing to talk to your doctor about your next treatment



Remember that you are your own best advocate

Doing your own research about available mCRPC treatments may help when you talk to your doctor about your next treatment option.

Your research may also help you understand what RLT is and how it works. Come prepared to share with your doctor what you've learned.

Only you can tell your doctor how you feel and what matters most in your life. Talk to your doctor honestly about what's important to you.



Consider bringing someone with you

It is important to remember details and to have emotional support when you talk to your doctor. Asking a family member or friend to go with you to your next appointment can help you keep track of everything you talk about.



Prepare your questions

Make sure you ask any questions that come up from your research.

There are also questions in this guide that may help you talk to your doctor about mCRPC treatment and decide if RLT is right for you.

Having a clear understanding of treatment options will help you and your doctor decide what is best for you

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Potential questions to ask during your doctor's visit

About RLT

What is RLT? How does it work?

How is RLT different from other treatments?

About an RLT called PLUVICTO

Based on my case, is PLUVICTO a treatment option for my mCRPC?

What is prostate-specific membrane antigen (PSMA)? How will I know if I'm PSMA positive?

How does PLUVICTO work?

What makes PLUVICTO different from other treatments I have had?

Is there anything that would stop me from taking PLUVICTO?

Please see additional Important Safety Information throughout and full Prescribing Information.

Potential questions to ask during your doctor's visit (continued)

About getting treatment with PLUVICTO

How is PLUVICTO administered? How often?

What kind of results can I expect with PLUVICTO?

What can I expect in my day-to-day life while taking PLUVICTO?

Will I need any laboratory or imaging tests during treatment?

Will I need to travel somewhere to receive PLUVICTO?

Please see additional Important Safety Information throughout and full Prescribing Information.

Potential questions to ask during your doctor's visit (continued)

About starting treatment with PLUVICTO

What are the next steps if PLUVICTO is right for me?

How can I find out where to get treatment with PLUVICTO?

Will my insurance cover treatment with PLUVICTO?

What things do I need to consider when planning to travel to and from treatment?

Are there any steps I need to take at home while being treated with PLUVICTO?

How much will treatment with PLUVICTO cost me?

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Potential questions to ask during your doctor's visit (continued)

About after treatment with PLUVICTO

What are some common side effects with PLUVICTO? How are they managed?

If I have concerns or experience any side effects, who should I call?

What to expect after talking to your doctor

Preparing for your appointment will help, but there is still a lot of information to understand and remember before committing to your next treatment. Call your doctor with any new questions that may come up after your visit.

Explore the PLUVICTO patient website to learn more

Visit pluvicto.com

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

IMPORTANT SAFETY INFORMATION

(continued)

Before you receive PLUVICTO, tell your doctor if any of these apply to you:

- You have low level of blood cell counts (hemoglobin, white blood cell count, absolute neutrophil count, platelet count)
- You have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty stopping bleeding, or frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (possible signs of myelosuppression)
- You have or have had kidney problems
- You have or have had any other type of cancer or treatment for cancer, as PLUVICTO contributes to your long-term cumulative radiation exposure
- You are sexually active as:
 - All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby
 - You should use effective contraception for intercourse during treatment with PLUVICTO and for 14 weeks after your last dose
 - PLUVICTO may cause temporary or permanent infertility

Before administration of PLUVICTO, you should drink plenty of water in order to urinate as often as possible during the first hours after administration.

The most common side effects of PLUVICTO include:

- Tiredness
- Dry mouth
- Nausea
- Low red blood cell count
- Loss of appetite
- Changes in bowel movements (constipation or diarrhea)
- Vomiting
- Low blood platelet count
- Urinary tract infection
- Weight loss
- Abdominal pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call [1-800-FDA-1088](tel:1-800-FDA-1088).

Please see full Prescribing Information.

Glossary of important terms

Overall response rate is defined as the percentage of patients in a clinical trial who respond to their assigned treatment.

Overall survival is defined as the total time clinical trial patients were alive from the start of treatment.

Positron emission tomography (PET) scan: A type of imaging that produces images of organs and tissues at work. It can be used to find cancer cells inside the body.

Progression-free survival is defined as how long a patient in a clinical trial lives without their disease getting worse after a treatment has been administered to them.

PSMA: Prostate-specific membrane antigen, or PSMA, is a protein biomarker that is found in higher amounts on prostate cancer cells. PSMA-positive (PSMA+) cells are identified on a PSMA PET scan.

Radioligand therapy (RLT): Radiation treatment that targets specific cells, including cancer cells.



Not actual patients.

It's never too late to ask questions
that are important to you

[Learn more about PLUVICTO](#)

**Please see additional Important Safety Information
throughout and full Prescribing Information.**



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2024 Novartis



4/24

426277